5.250

-0.670 (-11.32%)
Range 5.000 - 5.850   (17%)
Open 5.850
Previous Close 5.920
Buy Price 5.100
Buy Volume 12
Sell Price 5.200
Sell Volume 8
Volume 623,215
Value -
Remark
Measurement Type Value
EPS (USD) -1.428
Trailing EPS (USD) -0.416
NAV (USD) 0.455
Cash In Hand (USD) 0.107
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 13.014
Price / Cash In Hand 55.172
Issued & Paid-up Shares 10,562,400
Treasury Shares -
Market Cap (M) 62.529
Par Value (USD) n.a.
Beta - 75 Days 3.053
R-Squared - 75 Days(%) 4.77
Beta - 500 Days 2.68
R-Squared - 500 Days(%) 0.06
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 05 Mar 2021 05:00.
Data powered by
View All Events

About CANCER GENETICS INC

Cancer Genetics, Inc. (CGI) is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes. In August 2014, the Company acquired BioServe Biotechnologies (India) Pvt. Ltd.

Loading Chart...